ImproveCareNow Registry Used to Evaluate Use of Concomitant Immunomodulators with Adalimumab Therapy in Crohn’s Disease
Posted by Steve Steiner on August 23, 2016
Adalimumab (ADA) is an important biologic drug used in the treatment of pediatric Crohn’s disease. In May at Digestive Disease Week 2016, a meeting of gastroenterologists from around the world, Dr. Keith Benkov presented research examining variation in the use of Adalimumab monotherapy and concomitant therapy with an immunomodulator in pediatric Crohn’s disease. The cross-sectional analysis was completed using data from the ImproveCareNow Registry (known as “ICN2”).